Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Study acronym: FINALE
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 11 to 12
  2. Study sites: 10 to 11
    • Eligibility criteria expanded, about 9 words
  3. Study sites: 8 to 10v9
  4. Study sites: 6 to 8v8
  5. Study description expanded, about 15 wordsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 5 to 6v6
  2. Study sites: 4 to 5v5
  3. Primary completion date: Dec 2025 to Dec 2029
    • Study sites: 3 to 4
    • Start date changed from estimate of Sep 2023 to Oct 31, 2023
    v4
  4. Study sites: 2 to 3
    • Start date: Aug 2023 to Sep 2023
    v3
  5. Study sites: 1 to 2v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
Trial Details
NCT Number NCT05977751
Lead Sponsor Femasys Inc.
Conditions
(from sponsor)		 Contraception
Enrollment 573 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov